Ceftriaxone (Sandoz) is a medicine containing the active ingredient(s) ceftriaxone. On this page you will find out more about Ceftriaxone (Sandoz), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: ceftriaxone
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Ceftriaxone (Sandoz) 2 g powder for injection, 1 vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS: Treatment for the following infections when caused by susceptible aerobic organisims: 1 Lower respiratory tract infections. Caused by Strep.pneumoniae, Streptococcus sp. (excluding Enterococci), methicillin sensitive Staph.aureus, H.influenzae, H.parainfluenzae, Klebsiella sp. (including K.pneumoniae). E.coli, E.aerogenes, P.mirabilis and serratia marcescens. 2 Skin and skin structure infections. Caused by methicillin sensitive Staph.aureus, methicillin sensitive Staph.epidermidis, Streptococcus Group B, Streptococcus group G, Strep.pyogenes, Strep.virdans, Streptococcus sp. (excluding Enterococci), Peptostreptococcus sp., E.coli, E.cloacae, Klebsiella sp. (including K.pneumoniae and K.oxytoca), P.mirabilis, M.morganii and S.marcescens. 3 Urinary tract infections (complicated and uncomplicated). Caused by E.coli, P.mirabilis, P.vulgaris, M.morganii and Klebsiella sp. (including K.pneumoniea). 4 Uncomplicated gonorrhoea (cervical/urethral and rectal). Caused by N.gonorrhoeae, including both penicillinase and nonpenicillinase producing strains. 5 Bacterial septicaemia. Caused by Strep.pneumoniae, E.coli and H.influenzae. 6 Bone infections. Caused by methicillin sensitive Staph.aureus, methicillin sensitive Staph.epidermidis, Streptococcus group B, Strep.pneumoniae, Streptococcus sp. (excluding Enterocci), E.coli, Enterobacter sp., Pmirabilis and K.pneumoniae. 7 Joint infection. Caused by methicillin sensitive Staph.aureus, Strep.pneumoniae, Streptococcus sp. (excluding Enterococci), E.coli, P.mirabilis, K.pneumoniae and Enterobacter sp. 8 Menigitis. the initial treatment, as a single agent, of menigitis in children and immunocompetent adults when presumed or proven to be caused by H.influenzae type b, N.menigitidis, Strep.pneumoniae or Enterobacteriaceae pending culture and sensitivity results. 9 Surgical prophylaxis. The preoperative administration of a single 1g dose of ceftriaxone may reduce the incidence of postoperative infections in patients_undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures whic are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. 10Susceptibility testing. Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its sussceptibility ot the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
Table of characteristics
|Visual appearance||Clear glass vial containing a white to yellowish powder|
|Dosage Form||Injection, powder for|
|Route of administration||Intravenous|
1 vial: Prescription Only Medicine, or Prescription Animal Remedy
10 vials: Prescription Only Medicine, or Prescription Animal Remedy
5 vials: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Moisture,Protect from Light|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.